|Mr. William D. Clark M.B.A.||Pres, CEO & Director||821.39k||N/A||1969|
|Dr. Thomas A. Davis||Chief Medical Officer||631.72k||N/A||1964|
|Dr. Girish N. Aakalu Ph.D.||Chief Bus. Officer||536.42k||N/A||1975|
|Ms. Diantha Duvall||CFO & Sec.||N/A||N/A||1972|
|Dr. Jessica Baker Flechtner||Chief Scientific Officer||N/A||N/A||1972|
|Ms. Jacquelyn L. Sumer||Chief Legal & Compliance Officer||N/A||N/A||N/A|
|Dr. Raymond D. Stapleton Jr.||Exec. VP of Pharmaceutical Sciences & Manufacturing||N/A||N/A||1971|
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
Genocea Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.